Quest Diagnostics Ups FY Rev Guidance as 2Q Profit, Rev Rise

Dow Jones

2025/07/22

By Adriano Marchese

Quest Diagnostics raised its revenue guidance for the full year on higher demand and productivity gains after seeing profit and revenue growth in the second quarter.

The provider of diagnostic information services raised its revenue view for the full year to $10.8 billion to $10.92 billion, up from a previous expectation of between $10.7 billion and $10.85 billion.

Earnings, however, are expected lower, now projected to be between $8.60 and $8.80 a share, compared with the previous forecast for $8.62 to $8.87 a share. On an adjusted basis, the new range is for earnings to be between $9.63 and $9.83 a share, up from a previous range of $9.55 and $9.80 a share.

In the second quarter, net income came to $282 million, or $2.47 a share, up from $229 million, or $2.03 a share, in the same quarter a year ago.

Adjusted earnings were $2.62 a share. According to FactSet, analysts were expecting $2.57 a share.

Revenue rose 15% to $2.76 billion, which includes 5.2% growth from organic revenues, beating expectations of a rise to $2.73 billion.

Chairman and Chief Executive Jim Davis said the company benefited from demand for clinical solutions and expanded business from enterprise accounts that complemented growth from acquisitions.

"We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance," Davis said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

July 22, 2025 07:33 ET (11:33 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2553556732"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553556732\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553556732?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553556732","market":"hk","top_or_hot":-1,"title":"Quest Diagnostics Ups FY Rev Guidance as 2Q Profit, Rev Rise","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DGX\">Quest Diagnostics</a> raised its revenue guidance for the full year on higher demand and productivity gains after seeing profit and revenue growth in the second quarter. \n</p>\n<p>\n  The provider of diagnostic information services raised its revenue view for the full year to $10.8 billion to $10.92 billion, up from a previous expectation of between $10.7 billion and $10.85 billion. \n</p>\n<p>\n  Earnings, however, are expected lower, now projected to be between $8.60 and $8.80 a share, compared with the previous forecast for $8.62 to $8.87 a share. On an adjusted basis, the new range is for earnings to be between $9.63 and $9.83 a share, up from a previous range of $9.55 and $9.80 a share. \n</p>\n<p>\n  In the second quarter, net income came to $282 million, or $2.47 a share, up from $229 million, or $2.03 a share, in the same quarter a year ago. \n</p>\n<p>\n  Adjusted earnings were $2.62 a share. According to FactSet, analysts were expecting $2.57 a share. \n</p>\n<p>\n  Revenue rose 15% to $2.76 billion, which includes 5.2% growth from organic revenues, beating expectations of a rise to $2.73 billion. \n</p>\n<p>\n  Chairman and Chief Executive Jim Davis said the company benefited from demand for clinical solutions and expanded business from enterprise accounts that complemented growth from acquisitions. \n</p>\n<p>\n  \"We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance,\" Davis said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 22, 2025 07:33 ET (11:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quest Diagnostics Ups FY Rev Guidance as 2Q Profit, Rev Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuest Diagnostics Ups FY Rev Guidance as 2Q Profit, Rev Rise\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-07-22 19:33</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DGX\">Quest Diagnostics</a> raised its revenue guidance for the full year on higher demand and productivity gains after seeing profit and revenue growth in the second quarter. \n</p>\n<p>\n  The provider of diagnostic information services raised its revenue view for the full year to $10.8 billion to $10.92 billion, up from a previous expectation of between $10.7 billion and $10.85 billion. \n</p>\n<p>\n  Earnings, however, are expected lower, now projected to be between $8.60 and $8.80 a share, compared with the previous forecast for $8.62 to $8.87 a share. On an adjusted basis, the new range is for earnings to be between $9.63 and $9.83 a share, up from a previous range of $9.55 and $9.80 a share. \n</p>\n<p>\n  In the second quarter, net income came to $282 million, or $2.47 a share, up from $229 million, or $2.03 a share, in the same quarter a year ago. \n</p>\n<p>\n  Adjusted earnings were $2.62 a share. According to FactSet, analysts were expecting $2.57 a share. \n</p>\n<p>\n  Revenue rose 15% to $2.76 billion, which includes 5.2% growth from organic revenues, beating expectations of a rise to $2.73 billion. \n</p>\n<p>\n  Chairman and Chief Executive Jim Davis said the company benefited from demand for clinical solutions and expanded business from enterprise accounts that complemented growth from acquisitions. \n</p>\n<p>\n  \"We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance,\" Davis said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 22, 2025 07:33 ET (11:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1854104046.USD","symbol_name":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2553556732","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553556732","pubTimestamp":1753183980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Quest Diagnostics raised its revenue guidance for the full year on higher demand and productivity gains after seeing profit and revenue growth in the second quarter.The provider of diagnostic information services raised its revenue view for the full year to $10.8 billion to $10.92 billion, up from a previous expectation of between $10.7 billion and $10.85 billion.Earnings, however, are expected lower, now projected to be between $8.60 and $8.80 a share, compared with the previous forecast for $8.62 to $8.87 a share. On an adjusted basis, the new range is for earnings to be between $9.63 and $9.83 a share, up from a previous range of $9.55 and $9.80 a share.In the second quarter, net income came to $282 million, or $2.47 a share, up from $229 million, or $2.03 a share, in the same quarter a year ago.Adjusted earnings were $2.62 a share. According to FactSet, analysts were expecting $2.57 a share.\"We also realized productivity gains as we continued to deploy automation and digital techno","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","DGX":"奎斯特诊疗","BK4583":"猴痘概念","BK4588":"碎股","BK4196":"保健护理服务","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC"},"translate_title":"随着第二季度利润和营业额上升，Quest Diagnostics上调财年营业额指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DGX":1},"content_text":"By Adriano Marchese \n\n\n \n\n\nQuest Diagnostics raised its revenue guidance for the full year on higher demand and productivity gains after seeing profit and revenue growth in the second quarter. \n\n\n  The provider of diagnostic information services raised its revenue view for the full year to $10.8 billion to $10.92 billion, up from a previous expectation of between $10.7 billion and $10.85 billion. \n\n\n  Earnings, however, are expected lower, now projected to be between $8.60 and $8.80 a share, compared with the previous forecast for $8.62 to $8.87 a share. On an adjusted basis, the new range is for earnings to be between $9.63 and $9.83 a share, up from a previous range of $9.55 and $9.80 a share. \n\n\n  In the second quarter, net income came to $282 million, or $2.47 a share, up from $229 million, or $2.03 a share, in the same quarter a year ago. \n\n\n  Adjusted earnings were $2.62 a share. According to FactSet, analysts were expecting $2.57 a share. \n\n\n  Revenue rose 15% to $2.76 billion, which includes 5.2% growth from organic revenues, beating expectations of a rise to $2.73 billion. \n\n\n  Chairman and Chief Executive Jim Davis said the company benefited from demand for clinical solutions and expanded business from enterprise accounts that complemented growth from acquisitions. \n\n\n  \"We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance,\" Davis said. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 22, 2025 07:33 ET (11:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}